A phase II, single arm, open label, study on the safety and efficacy of quizartinib in newly diagnosed pediatric de novo FLT3-ITD positive/NPM1 wild type AML patients.
Latest Information Update: 27 Aug 2021
At a glance
- Drugs Quizartinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms QPiAML 2020
- 27 Aug 2021 New trial record